Expression of Com‐1/P8 in human breast cancer and its relevance to clinical outcome and ER status

Com‐1 is a recently discovered molecule that has putative action on the metastatic nature of cancer cells. The molecular action and clinical implication in cancer and prognosis are yet to be established. The current study examined the role of Com‐1 in a cohort of patients with breast cancer, with particular emphasis on its relationship with clinical outcomes and ER status. A panel of human breast cancer cell lines were tested. A cohort of breast cancer tumours (n‐120) with matched normal non‐neoplastic mammary tissues (n = 32) were used. Expression of Com‐1 in cancer cells and mammary tissues were studied using conventional and real‐time quantitative PCR. Expression profile was analysed against clinical information including tumour grade, staging, nodal status, ER status and survival of the patients. Statistical analysis was Mann‐Whitney U‐test and Cox Proportion analysis. Com‐1 was expressed in breast cancer cell lines. Com‐1 protein staining was primarily found in nucleus of epithelial cells of mammary tissues. Tumour cells in breast tissues exhibited a significant reduction in nuclear staining of Com‐1, compared to normal epithelial cells (p = 0.0061). Breast tumour tissues expressed similar levels of Com‐1, compared to normal non‐neoplastic mammary tissues (p = 0.62). There was, however, a stepwise decrease in tumours from patients with predicted good, moderate, to poor prognosis (using Nottingham Prognostic Index) (166 ± 135 copies of Com1 transcript, 44.3 ± 36 and 0.64 ± 0.24, respectively, p = 0.06 by Kruskal‐Wallis test). Likewise, node positive tumours had low levels of Com‐1, compared to node negative tumours. Tumours from patients who developed metastasis (11.4 ± 7 copies of Com1 transcript), had local recurrence (41.5 ± 3.7 copies of Com1 transcript), or who died of breast cancer (0.058 ± 0.03 copies of Com1 transcript) had lower levels of Com‐1, when compared to tumours from patients who remained disease free (156 ± 129 copies of Com1 transcript). There was no significant correlation between Com‐1 and overall survival or disease free survival. When ER status were taken into consideration, it was demonstrated that low levels of Com‐1 in ER‐β positive tumours were highly correlated with shorter overall survival of the patients (p = 0.018) (median follow‐up 120 months). Com‐1 is a nuclear protein, whose expression is reduced in human breast cancer tissues and cancer cell lines. The loss of Com‐1 protein is primarily from the nuclear compartment in cancer cells. The expression levels of Com‐1 in breast tumours are correlated with the prognosis of the patients and with the long term overall survival in association with ER status. © 2005 Wiley‐Liss, Inc.

[1]  W. Jiang,et al.  Com-1/P8 in oestrogen regulated growth of breast cancer cells, the ER-beta connection. , 2005, Biochemical and biophysical research communications.

[2]  G. Watkins,et al.  Differential expression of the CCN family members Cyr61, CTGF and Nov in human breast cancer. , 2004, Endocrine-related cancer.

[3]  Troy Stevens,et al.  Open Access Activated Leukocyte Cell Adhesion Molecule in Breast Cancer: Prognostic Indicator , 2022 .

[4]  J. Hartman,et al.  Estrogen receptor β inhibits 17β-estradiol-stimulated proliferation of the breast cancer cell line T47D , 2004 .

[5]  G. Firestone,et al.  Estrogen Receptor β Inhibits Human Breast Cancer Cell Proliferation and Tumor Formation by Causing a G2 Cell Cycle Arrest , 2004, Cancer Research.

[6]  J. Hartman,et al.  Estrogen receptor beta inhibits 17beta-estradiol-stimulated proliferation of the breast cancer cell line T47D. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[7]  G. Watkins,et al.  Prognostic value of rho GTPases and rho guanine nucleotide dissociation inhibitors in human breast cancers. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[8]  A. Miyauchi,et al.  Expression and cellular localization of p8 protein in thyroid neoplasms. , 2003, Cancer letters.

[9]  J. Iovanna,et al.  Research p 8 inhibits the growth of human pancreatic cancer cells and its expression is induced through pathways involved in growth inhibition and repressed by factors promoting cell growth , 2016 .

[10]  R. Mansel,et al.  Expression of peroxisome‐proliferator activated receptor‐gamma (PPARγ) and the PPARγ co‐activator, PGC‐1, in human breast cancer correlates with clinical outcomes , 2003 .

[11]  R. Feil,et al.  p8-deficient fibroblasts grow more rapidly and are more resistant to adriamycin-induced apoptosis , 2002, Oncogene.

[12]  J. Dagorn,et al.  p8 is critical for tumour development induced by rasV12 mutated protein and E1A oncogene , 2002, EMBO reports.

[13]  J. Iovanna,et al.  Overexpression of p8 is inversely correlated with apoptosis in pancreatic cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[14]  J. Iovanna,et al.  Expression of p8 in human pancreatic cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[15]  C. Hansen,et al.  Expression of a novel factor, com1, is regulated by 1,25-dihydroxyvitamin D3 in breast cancer cells. , 2000, Cancer research.

[16]  M. Brentani,et al.  Expression of a novel factor, com1, in early tumor progression of breast cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[17]  W. Jiang,et al.  Cell-cell adhesion molecules and signaling intermediates and their role in the invasive potential of prostate cancer cells. , 2000, The Journal of urology.

[18]  J. Iovanna,et al.  Cloning and expression of the human p8, a nuclear protein with mitogenic activity. , 2001, European journal of biochemistry.

[19]  E. Hovig,et al.  Expression of a novel factor in human breast cancer cells with metastatic potential. , 1999, Cancer research.

[20]  J. Iovanna,et al.  Cloning and Expression of the Rat p8 cDNA, a New Gene Activated in Pancreas during the Acute Phase of Pancreatitis, Pancreatic Development, and Regeneration, and Which Promotes Cellular Growth* , 1997, The Journal of Biological Chemistry.

[21]  I. Nazarenko,et al.  A closed tube format for amplification and detection of DNA based on energy transfer. , 1997, Nucleic acids research.

[22]  F. Sigaux,et al.  The MTCP-1/c6.1B gene encodes for a cytoplasmic 8 kD protein overexpressed in T cell leukemia bearing a t(X;14) translocation. , 1994, Oncogene.